WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s New Drug Application (NDA) for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease (GERD), and for the treatment of symptomatic GERD. The application is based on results from six recently completed Phase III studies involving more than 4,000 patients.
